Market 2018-04-05 (FB, MU, Trade War, and more)
Treasury: 30-year -0.47%. 10-yr -0.12%. 5-yr -0.08%. TLT -0.74%.
Crude +0.39% to $63.62. Gold -0.81% to $1,329.40. UUP +0.38%.
Atlanta Fed President Raphael Bostic, a voting member on FOMC, said in an interview that he is comfortable with inflation rising above the Fed's 2% target, which suggests he may favor a less aggressive approach to raising interest rates.
Winners
TSLA +6.5%. It has recovered from $245 to $305 in a week despite the company missing Q1 production target, facing Chinese Tariffs, possible risks of burning cash and raising equity.FB +2.7% after Zuckerberg answered reporters' questions. Deutsche Bank says worst is over.
AMD +2.6% upgraded by Stifel.
Energy sector is strong today: MRO +5.7%, RRC +5.4%, EQT +4.1%, NFX +3.6%, CVX +2.5%...
Agriculture stocks bounce back: MOS +4.5%, FMC +4.4%, CF +4%...
Losers
MU -6.7%, UBS initiates MU with a Sell rating and $35 PT. Firm says Micron is likely two quarters away from “significant estimate cuts” as a “wave of DRAM supply” comes closer. LRCX -3.3%, AMAT -2.3%, NVDA -2.2%, WDC -2.1%.Biotech falls again, IBB -1.6%: VRTX -2.8%, BIIB -2.7%, REGN -2.6%, CELG -1.8%. Barclays cut its PT on BIIB to $295 from $395.
After-hour
PriceSmart (PSMT -0.2%): Q2 EPS of $0.47 may not be comparable to consensus of $0.74.Revenue of $839.56M (+5.8% Y/Y) beats by $3.54M. Shares +3.3%.
The FDA designates Celgene's (CELG -1.8%) POMALYST (pomalidomide) an Orphan Drug for the treatment of Kaposi sarcoma, a type of opportunistic cancer that strikes people with weakened immune systems such as AIDS patients.
Dumb Trump is asking for tariffs on another $100B Chinese goods. Futures are falling. We will have another bloody day.
My Trades Today
Sold 1/3 TELL @ $8.5 (finally having profit on this one, average cost $8.3, reducing weight with PT $10).Sold 1/5 LUV @ $57.
Sold 1/5 C @ $70.8.
What’s your opinion on NVDA, worthy holding? Thanks!
ReplyDeleteYes, of course. AI and augmented reality are the future. Graphic processing (GPU) is the most important element. NVDA is ahead of peers by a lot. In the past two quarters, revenue were growing more than 30%. It was more than 50% from 16Q3 to 17Q2. NVDA has beaten ERs for the past 10 quarters. I am still holding some shares, will buy more if it drops to $210 or lower.
DeleteThanks for such a wonderful blog.
ReplyDeletehardness testing machine
melt flow indexer